About Pacific Edge
Pacific Edge is a company based in Dunedin (New Zealand) founded in 2011. Pacific Edge has raised $1.75 million across 1 funding round. Pacific Edge offers products and services including Cxbladder. Pacific Edge operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Dunedin, New Zealand
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pacific Edge Limited
-
Annual Revenue
$12.41 M (USD)-8.62as on Mar 31, 2025
-
Net Profit
-$17.01 M (USD)-1.36as on Mar 31, 2025
-
EBITDA
-$16.99 M (USD)7.38as on Mar 31, 2025
-
Total Equity Funding
$1.75 M (USD)
in 1 rounds
-
Latest Funding Round
$1.75 M (USD), Series A
Jul 30, 2018
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pacific Edge
Pacific Edge is a publicly listed company on the NZX with ticker symbol PEB in New Zealand, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pacific Edge
Pacific Edge offers a comprehensive portfolio of products and services, including Cxbladder.
Non-invasive urine-based test for detecting and monitoring bladder cancer.
People of Pacific Edge
Unlock access to complete
Unlock access to complete
Funding Insights of Pacific Edge
Pacific Edge has successfully raised a total of $1.75M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.75 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Pacific Edge
Investment portfolio details for Pacific Edge
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pacific Edge
Detailed financials for Pacific Edge
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pacific Edge Comparisons
Peer comparison for Pacific Edge
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pacific Edge
Pacific Edge operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Pacific Edge
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pacific Edge
Complete news archive for Pacific Edge
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pacific Edge
Pacific Edge was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Pacific Edge is headquartered in Dunedin, New Zealand. It is registered at Dunedin, Otago, New Zealand.
Pacific Edge is a funded company, having raised a total of $1.75M across 1 funding round to date.
Annual revenue of Pacific Edge is $12.41M as on Mar 31, 2025.
Pacific Edge was established in 2011 in Dunedin, New Zealand, within the biotechnology sector focused on cancer diagnostics. Urine-based tests, including the lead product Cxbladder, are offered to evaluate bladder cancer risk in hematuria patients via five protein biomarkers. Prognostic tools for colorectal, melanoma, endometrial, and gastric cancers are being developed to support clinical decision-making in oncology.
Pacific Edge's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Pacific Edge offers Cxbladder.
Yes, Pacific Edge is publicly traded on NZX under the ticker symbol PEB.
The ticker symbol of Pacific Edge is PEB on NZX.